Results 101 to 110 of about 51,662 (290)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Figure S7 from Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma

, 2023
Salvia Jain, Abigail Washington, Rebecca Karp Leaf, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Dina Stroopinsky, Athalia R. Pyzer, Leandra Cole, Myrna Nahas, Arie Apel, Jacalyn Rosenblatt, Jon Arnason, Donald Küfe, David Avigan   +14 more
openalex   +1 more source

NF‐κB Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor‐Resistant Cutaneous T‐Cell Lymphoma

Cancer Science, EarlyView.
We identified a novel mechanism of resistance to histone deacetylase inhibitors (HDACi) in cutaneous T‐cell lymphoma (CTCL), mediated by NF‐κB activation. This finding highlights NF‐κB as a potential therapeutic target for overcoming HDACi resistance in CTCL.
Yuto Takahashi, Akihiro Kitadate, Sayaka Iwama, Wataru Kuroki, Ko Abe, Masahiro Yamada, Sho Ikeda, Hiroyuki Tagawa, Hideki Wakui, Masaki Hikida, Naoto Takahashi   +10 more
wiley   +1 more source

Cutaneous involvement in angioimmunoblastic T-cell lymphoma

Indian Journal of Dermatology, 2010
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive non-Hodgkin′s nodal peripheral T-cell lymphoma characterized by general lymphadenopathy, night sweats, fever, hepatosplenomegaly, polyclonal hypergammaglobulinemia, and cutaneous ...
Papadavid Evangelia, Panayiotides Ioannis, Dalamaga Marianna, Katoulis Alexandros, Economopoulos Theofanis, Stavrianeas Nikolaos   +5 more
doaj  

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

What the Eyelid Can Tell You: The Unexpected Initial Presentation of De Novo Stage IV Breast Carcinoma

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT A 66‐year‐old female presented with seven months of progressive right upper eyelid (RUL) drooping and thickening of her right lower eyelid (RLL). MRI revealed soft tissue enhancement of the RUL and RLL pre‐septal planes without posterior extension.
Grace L. Casado, Eileen Xu, Maedot A. Haymete, Nicholas A. Ramey, Douglas J. Grider   +4 more
wiley   +1 more source

Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (PCAECTCL) is a rare and aggressive malignancy, with limited documented cases in pediatric patients. This report presents a unique case of a 9‐year‐old female with PCAECTCL, characterized by widespread erythematous annular lesions that exhibited an indolent clinical ...
Carrie Meng, Auris Huen, David McCall, Phyu P. Aung, Priyadharsini Nagarajan, Valentina Nardi, Carlos A. Torres‐Cabala   +6 more
wiley   +1 more source

High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma

, 2009
Peter Reimer
openalex   +1 more source

Cutaneous T-cell lymphoma

Indian Journal of Medical Research, 2020
Arora, Shalabh, Gogia, Ajay
openaire   +2 more sources

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser   +10 more
wiley   +1 more source